Listen

Press releases

Receive e-mail alerts

Internal link ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
May 01, 2017 at 11:00 AM UTC
Internal link ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
April 27, 2017 at 11:00 AM UTC
Internal link ProQR to Present at the Deutsche Bank Health Care Conference
April 20, 2017 at 11:00 AM UTC
Internal link ProQR Announces Annual Meeting of Shareholders
April 10, 2017 at 11:00 AM UTC
Internal link ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
April 03, 2017 at 11:00 AM UTC
Internal link ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
March 27, 2017 at 11:00 AM UTC
Internal link ProQR to Present at Two Upcoming Investor Conferences in March
March 01, 2017 at 12:00 PM UTC
Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
February 28, 2017 at 12:00 PM UTC
Internal link On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
February 27, 2017 at 12:00 PM UTC
Internal link ProQR to Present at the LEERINK Partners Global Healthcare Conference
February 07, 2017 at 12:00 PM UTC
Internal link ProQR Announces Results for the Third Quarter of 2016
November 14, 2016 at 12:00 PM UTC
Internal link ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients
October 27, 2016 at 11:00 AM UTC
Internal link ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC
September 27, 2016 at 11:00 AM UTC
Internal link ProQR to Present at Scientific and Investor Conferences in September
September 06, 2016 at 11:00 AM UTC
Internal link ProQR Announces Results for the Second Quarter of 2016
August 17, 2016 at 11:00 AM UTC
Internal link ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis
July 19, 2016 at 11:00 AM UTC
Internal link ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC
June 21, 2016 at 01:00 PM UTC
Internal link ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation
June 01, 2016 at 11:00 AM UTC
Internal link ProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference
June 01, 2016 at 11:00 AM UTC
Internal link ProQR Announces Results for the First Quarter of 2016
May 18, 2016 at 11:00 AM UTC
Internal link ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-110 for LCA10 at the 2016 ARVO Annual Meeting
April 25, 2016 at 08:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders
April 07, 2016 at 11:00 AM UTC
Internal link ProQR to Highlight a Growing Pipeline During a Research & Development Day and Present at the Barclays Global Healthcare Conference
March 01, 2016 at 12:00 PM UTC
Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2015
February 17, 2016 at 12:00 PM UTC
Internal link ProQR to Present at the Leerink Partners Global Healthcare Conference
February 03, 2016 at 12:00 PM UTC

Press releases

Internal link ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

Internal link ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

Internal link ProQR to Present at the Deutsche Bank Health Care Conference

Internal link ProQR Announces Annual Meeting of Shareholders

Internal link ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU

Internal link ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer

Internal link ProQR to Present at Two Upcoming Investor Conferences in March

Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update

Internal link On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day

Internal link ProQR to Present at the LEERINK Partners Global Healthcare Conference

Internal link ProQR Announces Results for the Third Quarter of 2016

Internal link ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients

Internal link ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC

Internal link ProQR to Present at Scientific and Investor Conferences in September

Internal link ProQR Announces Results for the Second Quarter of 2016

Internal link ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis

Internal link ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC

Internal link ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation

Internal link ProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference

Internal link ProQR Announces Results for the First Quarter of 2016

Internal link ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-110 for LCA10 at the 2016 ARVO Annual Meeting

Internal link ProQR Announces Annual Meeting of Shareholders

Internal link ProQR to Highlight a Growing Pipeline During a Research & Development Day and Present at the Barclays Global Healthcare Conference

Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2015

Internal link ProQR to Present at the Leerink Partners Global Healthcare Conference